Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the pricing of its initial public offering of 6,500,000 American Depositary Shares, each representing 12 ordinary shares of Stealth, at an initial public offering price of $12.00 per share. The total gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Stealth, are expected to be $78 million. The offering closed on February 20, 2019.

The WilmerHale team led by Rosemary G. Reilly included Chris Barnstable-Brown, Molly Fox, Sean Linnehan, Libby Ragan and Erin Garrity. Other attorneys who assisted the transaction include Rich Andersen, Bill Caporizzo, Kim Wethly, Bruce Manheim, Tim Silva, Heidi Treiber, Seth Davis and Ben Kelsey.